KISS1 and non-small cell lung carcinoma: Karapanagiotou et al. measured circulating levels of kisspeptin in 96 NSCLC patients (76 with metastatic disease and 21 with locally advanced disease) and detected no difference in plasma kisspeptin levels between NSCLC patients and healthy volunteers or between locally advanced and metastatic disease patients (72).